HAKAN GÜNEŞ, Tarik KIVRAK, MUSTAFA ADEM TATLISU, HAKKI KAYA, Dursun AKASLAN, Mehmet Birhan YILMAZ

Monosit Sayısı Dekompanse Kalp Yetersizliğinde Belirteç midir?

Monosit Sayısı Dekompanse Kalp Yetersizliğinde Belirteç midir? Giriş: Çalışmanın amacı akut dekompanse kalp yetersizliği (ADKY) olan hastalarda kardiyovasküler mortalite ile monosit sayısı arasındaki ilişkinin araştırılmasıdır. Gereç ve Yöntem: Çalışma kardiyolojiye ardışık başvurmuş 237 hasta içeren retrospektif kohort çalışmasıdır. Klinik takipler telefon görüşmesi veya hastanenin medikal kayıtlarından yapıldı. Bulgular: Hastalar iki gruba ayrıldı: 1. Grup takipte veya hastanede yatışı sırasında ölenlerden, 2. grup yaşayan hastalardan oluşturuldu. İki grup arasında monosit yüzdesi ve sayısı arasında anlamlı farklılık vardı (p=0.003; p=0.006, sırasıyla). ROC eğrisi ile değerlendirildi (AUC=0.618, %95 GA:0.544-0.693, p=0.003). Sonuç: Monosit ile ilişkili sitokinler ADKY de önemli rol oynarlar. Çalışmamız monositlerin ADKY olan hastalarda mortalitenin bağımsız prediktörü olabileceği, ucuz ve kolay ulaşılabileceğini gösterdi. Bununla birlikte geniş çaplı ve çok merkezli çalışmalar ile bulgular desteklenmelidir.

Is Monocyte Count a Marker in the Decompensation of Heart Failure?

Objective: The aim of this study is to investigate the association of monocytes count with cardiovascular mortality in patients with acute decompensated heart failure (ADHF). Material and Method: The study is a retrospective cohort study including 237 consecutive patients with ADHF admitted to cardiology. Clinical follow-up was performed by telephone interviews with the patient and/or relatives and by review of hospital medical records. Results: These patients were divided into two groups: the deceased group (group 1), who died during hospitalization or the follow-up period, and the survival group (group 2). There was a significant difference in the mean percentage of monocytes and monocyte count between the two groups (p=0.003; p=0.006, respectively). ROC curve was drawn (AUC=0.618, 95% confidence interval: 0.544-0.693, p=0.003). Conclusion: In summary monocyte-related cytokines play an important role in ADHF. Our study shows that monocytes can be used in patients with ADHF as a independent predictor of mortality; moreover it is inexpensive and easy to perform. Nonetheless, further larger-scale and multicenter studies needed to confirm these findings.

PDF

___

1. Dec GW. Management of acute decompensated heart failure. Curr Probl Cardiol 2007; 32: 321-66.
2. Summers RL, Sterling S. Early emergency management of acute decompensated heart failure. Curr Opin Crit Care 2012; 18: 301-7.
3. Onwuanyi A, Taylor M. Acute decompensated heart failure: pathophysiology and treatment. Am J Cardiol 2007 26; 99: 25-30.
4. Corrêa CR, Dias-Melicio LA, Calvi SA, Lastória S, Soares AM. Activation of monocytes and cytokine production in patients with peripheral atherosclerosis obliterans. J Inflamm 2011; 8: 23 doi:10.1186/1476-9255-8-23.
5. Haugen E, Gan LM, Isic A, Skommevik T, Fu M. Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients. Exp Clin Cardiol 2008; 13: 19-24.
6. Ali S, Shahbaz AU, Nelson MD, et al. Reduced relative lymphocyte count in African-Americans with decompensated heart failure. Am J Med Sci 2009; 337: 156-60.
7. Korkmaz L, Kul S, Korkmaz AA, et al. Increased leucocyte count could predict coronary artery calcification in patients free of clinically apparent cardiovascular disease. Arch Turk Soc Cardiol 2012; 40: 223-8.
8. Vaduganathan M, Greene SJ, Butler J, Sabbah HN et al. The immunological axis in heart failure: Importance of the leukocyte differential. Heart Fail Rev 2013; 18: 835-45.
9. Lepage S. Acute decompensated heart failure. Can J Cardiol 2008; 24: 8-10.
10. Vaduganathan M, Greene SJ, Butler J, et al. The immunological axis in heart failure: Importance of the leukocyte differential. Heart Fail Rev 2013; 18: 835-45.
11. Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Differential white blood cell count and incident heart failure in men and women in the EPICNorfolk study. Eur Heart J 2012; 33: 523-30.
12. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the antiinflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond) 2003; 105: 45-50.
13. Amin A. Hospitalized patients with acute decompensated heart failure: recognition, risk stra-tification, and treatment review. J Hosp Med 2008; 3: 16-24.
14. Varughese S. Management of acute decompensated heart failure. Crit Care Nurs Q 2008; 94-103.
15. Givertz MM, Teerlink JR, Albert NM, et al. Acute decompensated heart failure: Update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-89.
16. Schulze PC, Biolo A, Gopal D, et al. Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Card Fail 2011; 17: 1004-11.
17. Miettinen KH, Lassus J, Harjola V-P, et al. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute de-compensated heart failure. Eur J Heart Fail 2008; 10: 396-403.
18. Milani RV, Mehra MR, Endres S, et al. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest 1996; 110: 992-5.
19. Aukrust P, Ueland T, Müller F, Andreassen AK, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998; 97: 1136-43.
20. Makarewicz-Wujec M, Kozlowska-Wojciechowska M. Nutrient intake and serum level of gammaglutamyltransferase, MCP-1 and homocysteine in early stages of heart failure. Clin Nutr 2011; 30: 73-8.
21. Cappuzzello C, Di Vito L, Melchionna R, et al. Increase of plasma IL-9 and decrease of plasma IL- 5, IL-7, and IFN-? in patients with chronic heart failure. J Transl Med 2011; 21; 9-28.
22. Amir O, Spivak I, Lavi I, Rahat MA. Changes in the monocytic subsets CD14dimCD16+ and CD14++CD16- in chronic systolic heart failure patients. Mediators Inflamm 2012; 2012: 992-5.
23. Greene SJ, Harinstein ME, Vaduganathan M, et al. EVEREST Trial Investigators. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol 2012; 110: 1657- 62.
24. Shantsila E, Bialiuk N, Navitski D, et al. Blood leukocytes in heart failure with preserved ejection fraction: impact on prognosis. Int J Cardiol 2012; 155: 337-8.